Filing Flows › Comparisons › CHRS vs IVVD
Coherus Oncology vs Invivyd: CHRS and IVVD compared
Coherus Oncology is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $14.3M for Invivyd (Q2 2026). Coherus Oncology is growing faster (+40% against +21% a year earlier). Coherus Oncology is more profitable, with an operating margin of -226.0% against -320.8%.
Where the money goes: CHRS and IVVD
Coherus Oncology (CHRS) · Q2 2026
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
Invivyd (IVVD) · Q2 2026
Invivyd, Q2 2026: revenue $14.3M (+21% year over year), operating margin -320.8%, net loss $44.4M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
| Coherus Oncology (CHRS) | Invivyd (IVVD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $14.3M | $14.3M |
| Revenue growth, Y/Y | +40% | +21% |
| Operating margin | -226.0% | -320.8% |
| Net earnings | −$20.6M | −$44.4M |
| Net margin | -144.2% | -310.8% |
| Operating cash flow | −$62.1M | −$43.0M |
Where the revenue comes from
Coherus Oncology
- Toripalimab: $13.6M (95%)
- Other revenue: $694K (5%)
Questions
Which is bigger, Coherus Oncology or Invivyd?
Coherus Oncology is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $14.3M for Invivyd (Q2 2026).
Is Coherus Oncology or Invivyd growing faster?
Coherus Oncology is growing faster (+40% against +21% a year earlier).
Which is more profitable, Coherus Oncology or Invivyd?
Coherus Oncology is more profitable, with an operating margin of -226.0% against -320.8%.
More: Coherus Oncology earnings · how Coherus Oncology makes money · Invivyd earnings · how Invivyd makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.